CA3153944A1 - Anti-hemagglutinin antibodies and methods of use thereof - Google Patents
Anti-hemagglutinin antibodies and methods of use thereofInfo
- Publication number
- CA3153944A1 CA3153944A1 CA3153944A CA3153944A CA3153944A1 CA 3153944 A1 CA3153944 A1 CA 3153944A1 CA 3153944 A CA3153944 A CA 3153944A CA 3153944 A CA3153944 A CA 3153944A CA 3153944 A1 CA3153944 A1 CA 3153944A1
- Authority
- CA
- Canada
- Prior art keywords
- influenza
- antigen
- antibody
- binding fragment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926914P | 2019-10-28 | 2019-10-28 | |
| US62/926,914 | 2019-10-28 | ||
| US202063094170P | 2020-10-20 | 2020-10-20 | |
| US63/094,170 | 2020-10-20 | ||
| PCT/US2020/057635 WO2021086899A1 (en) | 2019-10-28 | 2020-10-28 | Anti-hemagglutinin antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3153944A1 true CA3153944A1 (en) | 2021-05-06 |
Family
ID=73498317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3153944A Pending CA3153944A1 (en) | 2019-10-28 | 2020-10-28 | Anti-hemagglutinin antibodies and methods of use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11773156B2 (https=) |
| EP (1) | EP4051707A1 (https=) |
| JP (1) | JP7611908B2 (https=) |
| KR (1) | KR20220088446A (https=) |
| CN (1) | CN114761428A (https=) |
| AU (2) | AU2020374878B2 (https=) |
| BR (1) | BR112022007923A2 (https=) |
| CA (1) | CA3153944A1 (https=) |
| CL (1) | CL2022001067A1 (https=) |
| CO (1) | CO2022005281A2 (https=) |
| IL (1) | IL292353A (https=) |
| MY (1) | MY207220A (https=) |
| PH (1) | PH12022550963A1 (https=) |
| WO (1) | WO2021086899A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023201306A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| WO2013114885A1 (en) | 2012-01-31 | 2013-08-08 | Osaka University | Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same |
| KR102228296B1 (ko) * | 2012-03-16 | 2021-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10639370B2 (en) * | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| JP6712428B2 (ja) | 2014-02-04 | 2020-06-24 | コントラフェクト コーポレイション | インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法 |
| EA201691945A1 (ru) * | 2014-03-27 | 2017-02-28 | Дженентек, Инк. | Антитела к гемагглютинину вируса гриппа типа b и способы их применения |
| CN119161468A (zh) * | 2014-07-15 | 2024-12-20 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| CN113480640B (zh) | 2015-06-01 | 2024-07-30 | 免疫医疗有限责任公司 | 中和抗流感结合分子及其用途 |
| US10696736B2 (en) * | 2015-06-03 | 2020-06-30 | Xiamen University | Broad-spectrum monoclonal anti-flu B antibody and uses thereof |
| CA3023143A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| KR102820941B1 (ko) * | 2018-01-26 | 2025-06-16 | 리제너론 파마슈티칼스 인코포레이티드 | 인플루엔자 헤마글루티닌에 대한 인간 항체 |
-
2020
- 2020-10-28 CN CN202080084529.XA patent/CN114761428A/zh active Pending
- 2020-10-28 KR KR1020227016672A patent/KR20220088446A/ko active Pending
- 2020-10-28 BR BR112022007923A patent/BR112022007923A2/pt unknown
- 2020-10-28 IL IL292353A patent/IL292353A/en unknown
- 2020-10-28 CA CA3153944A patent/CA3153944A1/en active Pending
- 2020-10-28 MY MYPI2022002059A patent/MY207220A/en unknown
- 2020-10-28 AU AU2020374878A patent/AU2020374878B2/en active Active
- 2020-10-28 PH PH1/2022/550963A patent/PH12022550963A1/en unknown
- 2020-10-28 EP EP20811191.4A patent/EP4051707A1/en active Pending
- 2020-10-28 US US17/082,375 patent/US11773156B2/en active Active
- 2020-10-28 WO PCT/US2020/057635 patent/WO2021086899A1/en not_active Ceased
- 2020-10-28 JP JP2022523575A patent/JP7611908B2/ja active Active
-
2022
- 2022-04-27 CO CONC2022/0005281A patent/CO2022005281A2/es unknown
- 2022-04-27 CL CL2022001067A patent/CL2022001067A1/es unknown
-
2023
- 2023-08-21 US US18/453,207 patent/US20240083983A1/en active Pending
-
2025
- 2025-11-21 AU AU2025271140A patent/AU2025271140A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4051707A1 (en) | 2022-09-07 |
| AU2025271140A1 (en) | 2026-01-22 |
| JP2022553703A (ja) | 2022-12-26 |
| US11773156B2 (en) | 2023-10-03 |
| AU2020374878B2 (en) | 2025-10-16 |
| WO2021086899A1 (en) | 2021-05-06 |
| US20240083983A1 (en) | 2024-03-14 |
| AU2020374878A1 (en) | 2022-04-28 |
| CN114761428A (zh) | 2022-07-15 |
| IL292353A (en) | 2022-06-01 |
| US20210171612A1 (en) | 2021-06-10 |
| BR112022007923A2 (pt) | 2022-07-26 |
| MY207220A (en) | 2025-02-06 |
| KR20220088446A (ko) | 2022-06-27 |
| CL2022001067A1 (es) | 2023-01-27 |
| CO2022005281A2 (es) | 2022-05-10 |
| PH12022550963A1 (en) | 2023-09-25 |
| JP7611908B2 (ja) | 2025-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11453714B2 (en) | Human antibodies to influenza hemagglutinin | |
| CA2974899A1 (en) | Human antibodies to ebola virus glycoprotein | |
| US11780907B2 (en) | Human antibodies to influenza hemagglutinin | |
| AU2025271140A1 (en) | Anti-hemagglutinin antibodies and methods of use thereof | |
| EA046393B1 (ru) | Антитела к гемагглютинину и их применение | |
| EA044791B1 (ru) | Человеческие антитела к гемагглютинину вируса гриппа |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240924 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240924 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250818 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250818 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250924 |